Arbutus Biopharma (ABUS) Return on Capital Employed (2014 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Return on Capital Employed of 86.54% for Q1 2026, up 16531.0% year-on-year from N/an in Q1 2025, and up 304.46% on a QoQ basis from 42.33% in Q4 2025.
Arbutus Biopharma (ABUS) Return on Capital Employed (2014 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Return on Capital Employed for 13 consecutive years, with 86.54% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed rose 16531.0% year-over-year to 86.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86.54% (up 16531.0% YoY) and the FY2025 annual result came in at 35.61%, up 2672.0% from the prior year.
- Return on Capital Employed advanced to 86.54% in Q1 2026 per ABUS's latest filing, from 42.33% in the prior quarter.
- Over the last five years, Return on Capital Employed for ABUS reached as high as 86.54% in Q1 2026 and fell as low as 78.77% in Q1 2025.
- A 5-year average of 43.66% and a median of 49.11% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 2128 bps — and 2026, when it surged 16531 bps.
- Year by year, Return on Capital Employed stood at 39.25% in 2022, then slumped by 54 bps to 60.53% in 2023, then fell by 5 bps to 63.36% in 2024, then soared by 33 bps to 42.33% in 2025, then soared by 304 bps to 86.54% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 86.54%, 42.33%, and 49.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 86.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.54% |
| Dec 31, 2025 | -42.33% |
| Sep 30, 2025 | -49.11% |
| Jun 30, 2025 | -56.68% |
| Mar 31, 2025 | -78.77% |
| Dec 31, 2024 | -63.36% |
| Sep 30, 2024 | -63.31% |
| Jun 30, 2024 | -62.80% |
| Mar 31, 2024 | -63.01% |
| Dec 31, 2023 | -60.53% |
| Sep 30, 2023 | -54.96% |
| Jun 30, 2023 | -47.76% |
| Mar 31, 2023 | -42.75% |
| Dec 31, 2022 | -39.25% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -32.71% |
| Mar 31, 2022 | -36.55% |
| Dec 31, 2021 | -42.30% |
| Sep 30, 2021 | -49.17% |
| Jun 30, 2021 | -49.89% |